Faran S Polani, Clinical Investigator at NEXT Oncology, Medical Oncologist at Texas Oncology shared a post on LinkedIn:
“Encouraging to see early clinical signals emerging in a space that has long been difficult to target, while recognizing there is still much to learn around patient selection, sequencing, and durability of response.
Excited to see how this field continues to evolve over the next few years.”
Title: KRASG12D Inhibitors: Understanding Early Efficacy Signals and Exploring Outstanding Questions
Authors: Faran Polani and Shiraj Sen
Read The Full Article
Other articles on OncoDaily.